Scandinavian Journal of Infectious Diseases

Taylor & Francis
Taylor & Francis
ISSN: 00365548, 16511980

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
journal names
Scandinavian Journal of Infectious Diseases
Publications
5 835
Citations
94 535
h-index
81
Top-3 citing journals
Clinical Infectious Diseases
Clinical Infectious Diseases (1305 citations)
PLoS ONE
PLoS ONE (1275 citations)
Top-3 organizations
Karolinska Institute
Karolinska Institute (53 publications)
Karolinska University Hospital
Karolinska University Hospital (44 publications)
Aarhus University Hospital
Aarhus University Hospital (22 publications)
Top-3 countries
Sweden (213 publications)
USA (94 publications)
Denmark (91 publications)

Most cited in 5 years

Found 
from chars
Publications found: 24792
Corrigendum to ‘OA09.04 Osimertinib with or without SRS for Brain Metastases from EGFRm NSCLC: Pooled Analysis of Two RCTs’ [Journal of Thoracic Oncology Vol. 19 No. 10S (2024) S28]
Ho C., Soon Y.Y., Nichol A., Robledo K., Sahgal A., Pinkham M., Melosky B., Huang Y., Parmar A., Solomon B., Liu M., Tham I.W., Sacher A., Tey J.C., Menjak I., et. al.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC with PD-L1 Expression ≥50%: 5-Year Outcomes of EMPOWER-Lung 1
Kilickap S., Baramidze A., Sezer A., Özgüroğlu M., Gumus M., Bondarenko I., Gogishvili M., Nechaeva M., Schenker M., Cicin I., Fuang H.G., Kulyaba Y., Zyuhal K., Scheusan R., Garassino M.C., et. al.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON)
Hakozaki T., Tanaka K., Shiraishi Y., Sekino Y., Mitome N., Okuma Y., Aiba T., Utsumi T., Tanizaki J., Azuma K., Hara S., Morita R., Niho S., Yokoyama T., Toyozawa R., et. al.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Selective depletion of CCR8+Treg cells enhances anti-tumor immunity of cytotoxic T cells in lung cancer via dendritic cells
Chen P., Wang H., Tang Z., Shi J., Cheng L., Zhao C., Li X., Zhou C.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Reply to: “AI Technologies for Patients With Immune-Related Adverse Events”
O’Reilly D., O’Leary C., Naidoo J.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
In this issue
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Navigating the Complexity of Cerebral Prophylaxis: A Path Worth Taking?
Ramella S., Fiore M., D’Angelillo R.M.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Reducing pERKs to Break “RAS”istance to Sotorasib
Gray S.G., O’Connor D., Mutti L., Meirson T.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Predictive Biomarker for SCLC Therapeutics: A Broken Promise or a Complex Disease With Missing Links
Chu Q.S.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Enlarging the Reach of Screening and Early Detection of Lung Cancer
Brown M., Myers R., Lam S.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
A Response to the Letter to the Editor: “Reply to Lei Wu et al.”
Kim E.K., Bak M.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Accurate Risk Factors of Cardiotoxicity in Patients With NSCLC Treated With Osimertinib
Wu L., Liu N., Sun M.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Patients With Resectable NSCLC Undergoing Neoadjuvant Chemoimmunotherapy: To Adjuvant or Not to Adjuvant?
Wu P., Li D., Zhang C., Sun N., He J.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 1
Artificial Intelligence Technologies for Managing High-Risk Patients With Immune-Related Adverse Events and Optimizing Timing
Liu F., Li H.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0

Top-100

Citing journals

500
1000
1500
2000
2500
3000
3500
4000
Show all (70 more)
500
1000
1500
2000
2500
3000
3500
4000

Citing publishers

5000
10000
15000
20000
25000
Show all (70 more)
5000
10000
15000
20000
25000

Publishing organizations

10
20
30
40
50
60
Show all (70 more)
10
20
30
40
50
60

Publishing countries

50
100
150
200
250
Sweden, 213, 3.65%
USA, 94, 1.61%
Denmark, 91, 1.56%
Finland, 63, 1.08%
Norway, 48, 0.82%
Turkey, 43, 0.74%
Italy, 41, 0.7%
China, 38, 0.65%
France, 37, 0.63%
Spain, 34, 0.58%
Greece, 28, 0.48%
United Kingdom, 25, 0.43%
Japan, 23, 0.39%
Germany, 22, 0.38%
Netherlands, 20, 0.34%
Israel, 14, 0.24%
Republic of Korea, 14, 0.24%
India, 12, 0.21%
Brazil, 10, 0.17%
Iceland, 10, 0.17%
Iran, 9, 0.15%
Canada, 9, 0.15%
Lebanon, 8, 0.14%
Switzerland, 8, 0.14%
Australia, 7, 0.12%
Austria, 6, 0.1%
Belgium, 6, 0.1%
Poland, 6, 0.1%
Estonia, 5, 0.09%
Bangladesh, 5, 0.09%
Slovakia, 5, 0.09%
Portugal, 4, 0.07%
Lithuania, 4, 0.07%
Pakistan, 4, 0.07%
Singapore, 4, 0.07%
Slovenia, 4, 0.07%
Czech Republic, 4, 0.07%
Chile, 4, 0.07%
Mexico, 3, 0.05%
Saudi Arabia, 3, 0.05%
Croatia, 3, 0.05%
Angola, 2, 0.03%
Bulgaria, 2, 0.03%
Guinea-Bissau, 2, 0.03%
Jordan, 2, 0.03%
New Zealand, 2, 0.03%
Senegal, 2, 0.03%
Thailand, 2, 0.03%
Tanzania, 2, 0.03%
Tunisia, 2, 0.03%
Russia, 1, 0.02%
Argentina, 1, 0.02%
Bosnia and Herzegovina, 1, 0.02%
Burkina Faso, 1, 0.02%
Hungary, 1, 0.02%
Venezuela, 1, 0.02%
Ghana, 1, 0.02%
Egypt, 1, 0.02%
Indonesia, 1, 0.02%
Ireland, 1, 0.02%
Qatar, 1, 0.02%
Cyprus, 1, 0.02%
Cuba, 1, 0.02%
Malaysia, 1, 0.02%
Nepal, 1, 0.02%
Nigeria, 1, 0.02%
UAE, 1, 0.02%
Oman, 1, 0.02%
Peru, 1, 0.02%
El Salvador, 1, 0.02%
Serbia, 1, 0.02%
Sudan, 1, 0.02%
Philippines, 1, 0.02%
Equatorial Guinea, 1, 0.02%
Ethiopia, 1, 0.02%
South Africa, 1, 0.02%
Kosovo, 1, 0.02%
Yugoslavia, 1, 0.02%
Show all (48 more)
50
100
150
200
250